

#26

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of : Gavin C. Hirst et al.,  
 Serial No. : 09/663,320  
 Filed : September 15, 2000  
 Entitled : KINASE INHIBITORS AS  
 THERAPEUTIC AGENTS

Attorney Docket No. BBC-081/A

ART UNIT: 1624

EXAMINER: Kim

**FAX RECEIVED**

FEB 13 2003

GROUP 1600

Asst. Commissioner for Patents  
 Box AF  
 Washington, D.C. 20231

**OFFICIAL****Certificate of Facsimile Transmission**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO facsimile number 703-872-9307 on the date set forth below.

FEBRUARY 12, 2003

Date of Signature and of Facsimile Transmission

By:

**TRANSMITTAL LETTER**

Sir/Madam:

Transmitted herewith are: [X] Request for Continued Examination to be filed in the above-identified patent application.

**FEE FOR ADDITIONAL CLAIMS**

[X] A fee for additional claims is not required.

[ ] A fee for additional claims is required. The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXCESS CLAIMS	RATE	FEE DUE
TOTAL CLAIMS			0	× \$18	= 0.00
INDEPENDENT			6	× \$84	= 0.00
FIRST INTRODUCTION OF MULT. DEPENDENT CLAIM				+\$280	= 0.00
TOTAL FEE DUE					=

02/21/2003 PATENT & TRADEMARK OFFICE 010005 09/663,320  
 01 FC:12

Application No.: 09/883,320  
Attorney Docket No.: BBC-081/A


**PAYMENT OF ADDITIONAL FEES**

- [X] The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 010025. A duplicate copy of this transmittal letter is transmitted herewith.

**PETITION FOR EXTENSION OF TIME**

- [ ] Extension is requested under 37 CFR 1.136(a), and the following extension fee is applicable for the paper(s) filed herewith: [ ] \$110.00 for response within first month pursuant to 37 CFR 1.17(a)(1);  
[X] \$400.00 for response within second month pursuant to 37 CFR 1.17(a)(2);  
[ ] \$920.00 for response within third month pursuant to 37 CFR 1.17(a)(3);  
[ ] \$1,440.00 for response within fourth month pursuant to 37 CFR 1.17(a)(4).  
[ ] \$1,960.00 for response within fifth month pursuant to 37 CFR 1.17(a)(5).
- [X] The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 010025. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,



Gayle B. O'Brien  
Agent for Applicants  
Registration No. 48,812  
Abbott Bioresearch Center, Inc.  
100 Research Drive  
Worcester, MA 01605-4314  
Telephone: (508) 688-8053  
Telefax: (508) 688-8110

#25

PTO/SB/30 (10/2001)  
 Approved for use through 10/31/2002 OMB 0681-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to:  
 Commissioner for Patents  
 Box RCE  
 Washington, DC 20231

Application Number	09/663,320
Filing Date	September 15, 2000
First Named Inventor	Gavin C. Hirst
Art Unit	1624
Examiner Name	B. Kifle
Attorney Docket Number	BBC081A

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995.

## 1. Submission required under 37 CFR §1.114

### a. ☒ Previously submitted

i. ☒ Consider the amendment(s)/reply under 37 CFR §1.116 previously filed on November 26, 2002  
 (Any unentered amendment(s) referred to above will be entered).

ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_

iii. ☐ Other \_\_\_\_\_

### b. ☒ Enclosed

i. ☐ Amendment/Reply

iii. ☐

Information Disclosure Statement (IDS)

ii. ☐ Affidavit(s)/Declaration(s)

iv. ☒

Other Petition for Extension of Time

## 2. Miscellaneous

a. ☐ Suspension of action on the above-identified application is requested under 37 CFR §1.103(c) for a period of \_\_\_\_\_ months (Period of suspension shall not exceed 3 months; Fee under 37 CFR §1.17(i) required)

b. ☐ Other \_\_\_\_\_

## 3. Fees

The RCE fee under 37 CFR §1.17(e) is required by 37 CFR §1.114 when the RCE is filed.

a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 01-0025

i. ☒ RCE fee required under 37 CFR §1.17(e)

ii. ☒ Extension of time fee (37 CFR §§1.136 and 1.17)

iii. ☐ Other \_\_\_\_\_

b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed

c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type) Gavin C. Hirst

Registration No. (Attorney / Agent) 48,812

Signature Gavin C. Hirst

Date February 12, 2003

## CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark

Name (Print/Type) Angela Perno

Signature Angela Perno

Date February 12, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.